4D Molecular Therapeutics Inc.
Organization details
- Legal name
- 4D Molecular Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Emeryville
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FDMT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001650648
- EIN
- 47-3506994
Board of directors
-
Charles Theuer · DirectorSince 2023
-
David Kirn · Director · See RemarksSince 2023
-
Glenn Sblendorio · DirectorSince 2026
-
Jacob Chacko · DirectorSince 2023
-
John F. Milligan · DirectorSince 2023
-
Nancy Miller-Rich · DirectorSince 2023
-
Noriyuki Kasahara · DirectorSince 2023
-
Shawn Tomasello · DirectorSince 2023
-
Susannah Gray · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
82.3%
-
96.5%
-
96.8%
Board connections
6 of this board's directors also sit on 9 other boards. 8 are in the same sector.
-
Aldeyra Therapeutics Inc. Same sectorvia Nancy Miller-Rich
-
AnaptysBio Inc. Same sectorvia Susannah Gray
-
Cabaletta Bio Inc. Same sectorvia Shawn Tomasello
-
Kailera Therapeutics Inc. Same sectorvia John F. Milligan
-
Kalaris Therapeutics Inc. Same sectorvia Shawn Tomasello
-
Maravai LifeSciences Holdings Inc. Same sectorvia Susannah Gray
-
Mineralys Therapeutics Inc. Same sectorvia Glenn Sblendorio
-
Oric Pharmaceuticals Inc. Same sectorvia Jacob Chacko
- via John F. Milligan
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $5,353,427
- 25 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 16, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
| Oct 16, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −1,635 | $12.84 | $20,993 |
| Oct 5, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −58,061 | $12.92 | $750,235 |
| Oct 5, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −272 | $13.61 | $3,702 |
| Sep 16, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
| Sep 16, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −1,635 | $13.65 | $22,318 |
| Sep 14, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −58,333 | $13.90 | $810,829 |
| Sep 1, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +584 | $6.49 | $3,790 |
| Sep 1, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −584 | $14.00 | $8,176 |
| Aug 19, 2026 | David Kirn Director, Officer (See Remarks) | Option exercise | +50,000 | $4.14 | $207,000 |
| Aug 19, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −43,149 | $15.36 | $662,769 |
| Aug 19, 2026 | David Kirn Director, Officer (See Remarks) | Open-market sale | −25,927 | $16.42 | $425,721 |
| Aug 17, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
| Aug 17, 2026 | Bizily Scott Officer (Chief Legal Officer) | Open-market sale | −1,635 | $12.20 | $19,947 |
| Aug 13, 2026 | Bizily Scott Officer (Chief Legal Officer) | Option exercise | +1,635 | $4.14 | $6,769 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about 4D Molecular Therapeutics Inc.
Who is the CEO of 4D Molecular Therapeutics Inc.?
David Kirn is 4D Molecular Therapeutics Inc.'s Chief Executive Officer.
How many directors are on 4D Molecular Therapeutics Inc.'s board?
4D Molecular Therapeutics Inc.'s board has 9 directors: Charles Theuer, David Kirn, Glenn Sblendorio, Jacob Chacko, John F. Milligan, Nancy Miller-Rich, Noriyuki Kasahara, Shawn Tomasello and Susannah Gray.
Are 4D Molecular Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, 4D Molecular Therapeutics Inc. insiders made no open-market purchases and sold $5.4 million of shares in 25 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="4d-molecular-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.